Arrayjet secures new contract to provide SciLifeLab with microarray technology for proteomics research
We note also the response of the European Association for Cardiothoracic Surgery (EACTS), which has withdrawn their support for the Left Main Chapter of the joint 2018 EACTS – ESC (European Society of Cardiology) Clinical Guidelines for Myocardial Revascularization.
The possibility that some patients may have been wrongly advised or treated as a result of current recommendations, which may have been influenced due to incomplete reporting of available data from the EXCEL trial, is a serious matter.
Our membership holds the veracity and transparency of data as fundamental tenets of clinical research trials; if any member of the treating heart teams, oversight committees, trial investigators, or peer reviewers raise potential serious issues regarding trial data presentation or interpretation, then the best way forward is the public release of all trial data for an independent analysis to confirm that the original trial conclusions are valid.
This is particularly true for industry sponsored trials of previously approved devices which are not subject to Government oversight, to reassure the public and physician community that conflicts of interest or unconscious bias has not influenced substantially the design, conduct, reporting, or interpretation of such studies.
The AATS agrees with others that all of the data should be made publicly available for analysis and interpretation, as a way to resolve the current controversy around the EXCEL trial, in order to provide patients with the best possible counsel and informed consent.
Vaughn A. Starnes, MD, President and David R. Jones, MD, Secretary Source:
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology